45 research outputs found

    Qualitative difference between the angular anisotropy parameters in fast electron scattering and photoionization

    Full text link
    It is demonstrated for the first time that in spite of well known big similarities between atomic ionization by photons and fast electrons, a qualitative difference exists in angular anisotropy parameters of electrons knocked out in these processes. The difference is disclosed here and attributed to distinction between normal (transverse) and virtual (longitudinal) photons. Formulas are derived for dipole and non-dipole angular anisotropy parameters in fast electronatom scattering. The ratio of quadrupole-to-dipole matrix elements is determined by the parameter \omega R/v << 1 where \omega is the transferred in collision energy, R is the ionized shell radius and v is the speed of projectile. This factor can be much bigger than in the case of photoionization, where one has the speed of light c that is much bigger than v . We illustrate general formulas by concrete results for outer s-subshells of noble gas atoms Ar and Xe. Even for very small transferred momentum q, in the so-called optical limit, the deviation from photoionization case is prominent and instructive.Comment: 8 pages, 3 figures. arXiv admin note: substantial text overlap with arXiv:1012.546

    Predictions for the future of kallikrein-related peptidases in molecular diagnostics

    Get PDF
    Kallikrein-related peptidases (KLKs) form a cancer-related ensemble of serine proteases. This multigene family hosts the most widely used cancer biomarker that is PSA-KLK3, with millions of tests performed annually worldwide. The present report provides an overview of the biomarker potential of the extended KLK family (KLK1-KLK15) in various disease settings and envisages approaches that could lead to additional KLK-driven applications in future molecular diagnostics. Particular focus is given on the inclusion of KLKs into multifaceted cancer biomarker panels that provide enhanced diagnostic, prognostic and/or predictive accuracy in several human malignancies. Such panels have been described so far for prostate, ovarian, lung and colorectal cancers. The role of KLKs as biomarkers in non-malignant disease settings, such as Alzheimer’s disease and multiple sclerosis, is also commented upon. Predictions are given on the challenges and future directions regarding clinically oriented KLK research

    Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts, supported by scanning electron microscopy

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Miltefosine, which is the first oral drug licensed for the treatment of leishmaniasis, was recently reported to be a promising lead compound for the synthesis of novel antischistosomal derivatives with potent activity <it>in vivo </it>against different developmental stages of <it>Schistosoma mansoni</it>. In this paper an <it>in vitro </it>study was carried out to investigate whether it has a biocidal activity against the aquatic stages of <it>Schistosoma mansoni </it>and its snail intermediate host, <it>Biomphalaria alexandrina </it>, thus being also a molluscicide. Additionally, to see whether miltefosine can have a broad spectrum antischistosomal activity, a similar <it>in vitro </it>study was carried out on the adult stage of <it>Schistosoma haematobium</it>, the second major human species, its larval stages and snail intermediate host, <it>Bulinus truncutes</it>. This was checked by scanning electron microscopy.</p> <p>Results</p> <p>Miltefosine proved to have <it>in vitro </it>ovicidal, schistolarvicidal and lethal activity on adult worms of both <it>Schistosoma </it>species and has considerable molluscicidal activity on their snail hosts. Scanning electron microscopy revealed several morphological changes on the different stages of the parasite and on the soft body of the snail, which further strengthens the current evidence of miltefosine's activity. This is the first report of mollusicidal activity of miltefosine and its <it>in vitro </it>schistosomicidal activity against <it>S.haematobium</it>.</p> <p>Conclusions</p> <p>This study highlights miltefosine not only as a potential promising lead compound for the synthesis of novel broad spectrum schistosomicidal derivatives, but also for molluscicidals.</p
    corecore